Evotec is a leading global drug discovery partnership organization with expertise in multiple therapeutics areas including infectious disease. Forge & Evotec formed a strategic relationship in 2016 to advance the LpxC program and expanded in 2017 to further develop the BLACKSMITH platform. In addition, Evotec is an investor in Forge’s Series A financing.

Syngene International

Forge partners with Syngene on select chemistry activities including analoging, building block synthesis, and scale-up. Syngene is India’s largest contract research organization.


CARB-X is the world’s largest public-private partnership dedicated to supporting the discovery of antibiotics targeting Gram-negative bacteria. CARB-X has over $450M in funding to support a portfolio of new innovative drug discovery programs. Forge was the largest recipient of the inagural CARB-X awards.


Forge has been collaborating with NIAID since 2015 to develop key datasets to help advance its anti-infective programs.


Forge has initiated a collaboration with USAMRIID to investigate medical counter measures for biodefense.


Forge is collaborating with Dr. Spellberg on the development of antibiotics to treat multi (MDR) and extensively drug resistant (XDR) bacteria infections.